loader image
- Advertisement -

Thursday, May 23, 2024
83.8 F
McAllen
- Advertisement -

DHR Health Receives FDA Approval to Offer Fourth Dose of Pfizer Covid-19 mRNA Vaccine

Translate text to Spanish or other 102 languages!

- Advertisement -
DHR Health Institute for Research & Development has been granted Expanded Access by the FDA to offer fourth dose of Pfizer COVID-19 mRNA vaccine. Image for illustration purposes
DHR Health Institute for Research & Development has been granted Expanded Access by the FDA to offer fourth dose of Pfizer COVID-19 mRNA vaccine. Image for illustration purposes

Texas Border Business

- Advertisement -

Edinburg, Texas – DHR Health Institute for Research & Development has been granted Expanded Access by the FDA to offer fourth dose of Pfizer COVID-19 mRNA vaccine. DHR Health Institute for Research & Development is the first and only entity in the US which has received formal approval from the FDA to administer the fourth dose of this vaccine.

“Recent clinical studies in Israel and other European countries have provided scientific evidence that the fourth dose of Pfizer COVID-19 mRNA vaccine affords enhanced protection against the Omicron variant” said Sohail Rao, MD, MA, DPhil, President and CEO, DHR Health Institute for Research & Development. “Given that Omicron is the dominant variant which is responsible for the current spike in COVID-19 cases in the US, we are pleased to offer this option to continue to keep our community safe”

To qualify for the fourth dose, you must be a healthcare worker, or above the age of 65 years, or have an immunocompromised status. The fourth dose can be administered 90 days after the third dose of the Pfizer COVID-19 mRNA vaccine. If you have been recently diagnosed with COVID-19, you can also receive the fourth dose 21 days after complete resolution of your symptoms. As part of this protocol, the level of antibodies against the virus that causes COVID-19 will also be measured in the blood before administering the fourth dose and at frequent intervals thereafter and the results of these tests will be provided to the patient in a timely manner.

- Advertisement -

If you or your patient is interested to receive the fourth dose, please call 956-362-2392 or 956-362-2387; or send an email dhrresearch@dhr-rgv.com; or fax with relevant patient information to 956-362-2383

- Advertisement -
- Advertisement -
- Advertisement -

Latest News

More Articles Like This

- Advertisement -